Biologically Active Small Molecules

A potent group IVA cPLA2 inhibitor (XI(50) = 0.022) reduces thermal hyperalgesia evoked by carrageenan injection of rat hind paw (ED₅₀ = 1.2 mg/kg) does not inhibit COX activity or interfere with CB1 receptor signaling.

A potent group IVA cPLA2 inhibitor (XI(50) = 0.022) reduces thermal hyperalgesia evoked by carrageenan injection of rat hind paw (ED₅₀ = 1.2 mg/kg) does not inhibit COX activity or interfere with CB1 receptor signaling.

A potent group IVA cPLA2 inhibitor (XI(50) = 0.022) reduces thermal hyperalgesia evoked by carrageenan injection of rat hind paw (ED₅₀ = 1.2 mg/kg) does not inhibit COX activity or interfere with CB1 receptor signaling.

A tyrosine kinase inhibitor that blocks the activation of VEGFR1, VEGFR2, VEGFR3, c-kit, and PDGFR-&beta (IC₅₀ = 1.2, 0.

A tyrosine kinase inhibitor that blocks the activation of VEGFR1, VEGFR2, VEGFR3, c-kit, and PDGFR-&beta (IC₅₀ = 1.2, 0.

A tyrosine kinase inhibitor that blocks the activation of VEGFR1, VEGFR2, VEGFR3, c-kit, and PDGFR-&beta (IC₅₀ = 1.2, 0.

A DHCR7 inhibitor that prevents cholesterol biosynthesis and Hedgehog signaling used to recapitulate phenotypes of Smith-Lemli-Opitz syndrome, a disorder brought about by mutations in the DHCR7 gene, in animal models.

A DHCR7 inhibitor that prevents cholesterol biosynthesis and Hedgehog signaling used to recapitulate phenotypes of Smith-Lemli-Opitz syndrome, a disorder brought about by mutations in the DHCR7 gene, in animal models.

A DHCR7 inhibitor that prevents cholesterol biosynthesis and Hedgehog signaling used to recapitulate phenotypes of Smith-Lemli-Opitz syndrome, a disorder brought about by mutations in the DHCR7 gene, in animal models.

A DHCR7 inhibitor that prevents cholesterol biosynthesis and Hedgehog signaling used to recapitulate phenotypes of Smith-Lemli-Opitz syndrome, a disorder brought about by mutations in the DHCR7 gene, in animal models.

A potent, selective inhibitor of ATR (IC₅₀ = 5 nM) inhibits the growth of LoVo colorectal adenocarcinoma cells in vitro and significantly reduces the growth of LoVo xenografts in mice.

A potent, selective inhibitor of ATR (IC₅₀ = 5 nM) inhibits the growth of LoVo colorectal adenocarcinoma cells in vitro and significantly reduces the growth of LoVo xenografts in mice.